ECHELON-2: Phase III Trial of Brentuximab Vedotin + CHP vs CHOP in Previously Untreated CD30+ Peripheral T-Cell Lymphomas

December 1-4, 2018; San Diego, California
Frontline BV + CHP achieved superior PFS and OS vs standard CHOP with a manageable safety profile, leading to the recent FDA approval in this setting.
Format: Microsoft PowerPoint (.ppt)
File Size: 260 KB
Released: December 11, 2018


Provided by the Annenberg Center for Health Sciences at Eisenhower.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs
Seattle Genetics
Takeda Oncology

Related Content

Gain key clinical insights fast, with this short slideset from CCO on biomarkers for imuno-onolcogy approaches in lung cancer

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 29, 2020

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of systemic therapy options for advanced HCC

Richard Finn, MD Released: October 29, 2020

Downloadable slides with expert analysis of BCMA-targeted agents for RR multiple myeloma from Clinical Care Options.

Natalie S. Callander, MD Released: October 26, 2020

Video featuring European experts on immune checkpoint inhibitors for treating early-stage through metastatic hepatocellular carcinoma, from CCO

Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 26, 2020 Expired: October 25, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.